Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cycloserine

FDA-approved product (capsule, oral), marketed as Seromycin.

Registered studies
50+
Lab records
6
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Cycloserine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Extrapulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB01

Repurposing investigation

Cycloserine is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA13.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae15.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis5.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 2 of 4 lab records
  • M. tuberculosis: measured active in 0 of 2 lab records
Open Cycloserine in ChEMBL Registered studies below
Show the 6 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-4.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-4.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-4.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cycloserine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects

    NCT00635102 · start 1997-10

    Registered record
    Registry ID
    NCT00635102
    Conditions
    Alcohol Dependence
    Interventions
    D-Cycloserine PO and Glycine IV; Placebo D-Cycloserine PO and placebo Glycine IV; Placebo D-Cycloserine PO and Glycine IV; D-Cycloserine PO and placebo Glycine IV
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1997-10
    Completion
    2008-02
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Dependence
    InterventionD-Cycloserine PO and Glycine IV; Placebo D-Cycloserine PO and placebo Glycine IV; Placebo D-Cycloserine PO and Glycine IV; D-Cycloserine PO and placebo Glycine IV
    PhaseNot applicable
    Registry statusCompleted

  • Trial of D-Cycloserine in Schizophrenia

    NCT00000371 · start 1996-08

    Registered record
    Registry ID
    NCT00000371
    Conditions
    Schizophrenia
    Interventions
    D-cycloserine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1996-08
    Completion
    2002-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionD-cycloserine; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

    NCT00000796

    Registered record
    Registry ID
    NCT00000796
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Cycloserine; Ethionamide; Capreomycin sulfate; Aminosalicylic acid; Streptomycin sulfate; Ethambutol hydrochloride; Amikacin sulfate; Isoniazid; Pyrazinamide; Pyridoxine hydrochloride; Levofloxacin; Rifampin; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1998-10
    Enrolment
    525

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionCycloserine; Ethionamide; Capreomycin sulfate; Aminosalicylic acid +9 more
    PhaseNot applicable
    Registry statusCompleted

  • Exploring Learning and Unlearning of Fear

    NCT01512316

    Registered record
    Registry ID
    NCT01512316
    Conditions
    Healthy Individuals
    Interventions
    d-Cycloserine; Lactose pill; Saliva sample; Functional neuroimaging (fMRI)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Individuals
    Interventiond-Cycloserine; Lactose pill; Saliva sample; Functional neuroimaging (fMRI)
    PhaseNot applicable
    Registry statusWithdrawn

  • NRX-101 Expanded Access

    NCT05779267

    Registered record
    Registry ID
    NCT05779267
    Conditions
    Treatment-Resistant Depression
    Interventions
    NRX-101; Transcranial Magnetic Stimulation Sham
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment-Resistant Depression
    InterventionNRX-101; Transcranial Magnetic Stimulation Sham
    PhaseNot recorded
    Registry statusAvailable